Shahid Beheshti University of Medical Sciences, Tehran, Iran
Abstract
In order to evaluate the effect of liothyronine formulated by Iran Hormone Co.(LT3,IH), 20 patients with primary hypothyroidism received 25mg LT3-IH daily. Another 40 hypothyroids were randomly divided into 4 groups and entered a double blind clinical trail. Two groups received 37.5 and 50mg LTrIH and other two groups took 37.5 and 50mg Cytomel (LTr SKF). Serum T4, T3 and TSH concentrations and resin T3 uptake were measured by commercial kits before and one month after intervention. After one month therapy with 25g LT3-IH, T3 increased from 80±33 to 142±36 ng/dl and TSH decreased from 58±24 to 0.5±0.7 /AJ/m\. Both LT3-IH and Cytomel increased T3 and decreased T4 and TSH concentration; TSH 62±28 & 81±39 before and 0.8±0.7 & 4.0±4.5 after one month of 37.5/;g T, daily; TSH 78±31 & 82±38 before and 0.5±0.4 & 0.4±0.6 ,mU/ml, respectively one months after daily ingestion of 50 mg LT3-IH and Cytomel, respectively. This study demonstrates similar effectiveness of LT3-IH and Cytomel in reduction of serum TSH and elevation of serum T3 in patients with hypothyroidism.
Azizi, F. (1996). Clinical evaluation of liothyronine (Iran Hormone): Comparison with Cytomel [Persian]. Iranian Journal of Nuclear Medicine, 4(1), 1-5.
MLA
Fereidoun Azizi. "Clinical evaluation of liothyronine (Iran Hormone): Comparison with Cytomel [Persian]". Iranian Journal of Nuclear Medicine, 4, 1, 1996, 1-5.
HARVARD
Azizi, F. (1996). 'Clinical evaluation of liothyronine (Iran Hormone): Comparison with Cytomel [Persian]', Iranian Journal of Nuclear Medicine, 4(1), pp. 1-5.
VANCOUVER
Azizi, F. Clinical evaluation of liothyronine (Iran Hormone): Comparison with Cytomel [Persian]. Iranian Journal of Nuclear Medicine, 1996; 4(1): 1-5.
)